AMERGE SUMMARY
AMERGE Tablets contain naratriptan as the hydrochloride, which is a selective 5-hydroxytryptamine1 receptor subtype agonist.
AMERGE Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.
AMERGE Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of AMERGE Tablets have not been established for cluster headache, which is present in an older, predominantly male population.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Amerge (Naratriptan)
Effective Migraine Prevention per 215 Trials
Source: Medscape Pharmacists Headlines [2013.06.11]
A recent meta-analysis compares the safety and efficacy of preventive pharmacologic therapies for episodic migraine.
Medscape Neurology
Epilepsy, Periodic Paralyses And Strokes Most Common Neurological Comorbidities Of Migraine Headaches In Children
Source: Headache / Migraine News From Medical News Today [2013.06.11]
Migraines in children and adolescents occur jointly with other neurological, psychiatric or somatic diseases with above-average frequency. Epilepsy, various disorders caused by cellular ion channels malfunction (channelopathies) and multiple sclerosis deserve special mention in this regard in the field of neurology...
Migraines Do Not Exacerbate Mental Deterioration
Source: Headache / Migraine News From Medical News Today [2013.06.11]
Migraines are more than just painful. Prof Franz Fazekas (University Hospital Graz, Austria), explained why at the 23rd Meeting of the European Neurological Society (ENS) in Barcelona: "Recent studies indicate that these pain attacks also pose an increased risk of vascular lesions in the brain in certain categories of patients...
Lifestyle Changes May Reduce Migraine Frequency
Source: Headache / Migraine News From Medical News Today [2013.06.10]
Some lifestyle changes, including getting adequate sleep, the right diet, exercise, and proper rehydration can help reduce the number of times you get migraines, says Dr. Robert Sheeler, who works at the Mayo Clinic, Rochester, Minnesota, USA. Dr Sheeler adds that even for people who do not get frequent migraines, they can have a major impact on their lives...
Abdominal Migraines in Children and Adults
Source: MedicineNet Abdominal Pain Specialty [2013.06.05]
Title: Abdominal Migraines in Children and Adults
Category: Diseases and Conditions
Created: 8/30/2012 7:04:00 PM
Last Editorial Review: 6/5/2013 12:00:00 AM
Published Studies Related to Amerge (Naratriptan)
Published and not fully published double-blind, randomised, controlled trials
with oral naratriptan in the treatment of migraine: a review based on the GSK
Trial Register. [2011]
Naratriptan 2.5 mg is now an over-the-counter drug in Germany.Naratriptan, when available OTC is a reasonable second or third
choice on the step care ladder in the acute treatment of migraine.
Efficacy of oral naratriptan in the treatment of menstrually related migraine. [2005.10]
The aim of this study was to investigate the efficacy of orally administered 2.5 mg naratriptan in the treatment of menstrually related migraine (MRM). A high percentage of women suffering from migraine report increased frequency of attacks in association with menstruation that may be more severe, of longer duration and more difficult to treat than at other times...
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. [2003.11]
This was a randomized, double-blind study designed to evaluate the comparative efficacy and tolerability of the 40-mg dose of eletriptan and the 2.5-mg dose of naratriptan. Patients (n = 548) meeting International Headache Society (IHS) criteria for migraine were randomized to treat a single migraine attack with either eletriptan 40 mg, naratriptan 2.5 mg, or placebo.
Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. [2003.09]
OBJECTIVE: To evaluate the effect of acute treatment on ictal behavioral functioning of patients with migraine via ambulatory accelerometry. BACKGROUND: The inability to carry out daily activities often complicates migraine attacks. Research into the effects of pharmacological drugs on this outcome parameter in the acute treatment of migraine has been based on subjective reports only... CONCLUSIONS: Consciously perceived clinical and subjective symptoms do not necessarily run in parallel with their behavioral equivalents. It, thus, may be important to assess the effects of treatment on behavioral functioning in the evaluation of the general efficacy of antimigraine drugs in the acute treatment of a migraine attack.
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. [2001.03]
OBJECTIVE: To determine the efficacy of naratriptan 1-mg and 2.5-mg tablets twice daily compared with placebo as short-term prophylaxis of menstrually associated migraine. BACKGROUND: Approximately 60% of women with migraine report headaches associated with their menstrual cycles. Results from an open-label study suggest that short-term administration of sumatriptan is useful in the prophylaxis of menstrually associated migraine... CONCLUSIONS: Naratriptan, 1 mg, with tolerability similar to placebo, is an effective, short-term, prophylactic treatment for menstrually associated migraine.
Clinical Trials Related to Amerge (Naratriptan)
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine. [Not yet recruiting]
The purpose of this study is to determine whether a fixed-dose combination of naratriptan
2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute
treatment of migraine.
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine [Not yet recruiting]
The purpose of this study is to determine whether a fixed-dose combination of naratriptan +
naproxen is effective compared each monotherapy for the acute treatment of migraine.
Sumatriptan and Naratriptan Pregnancy Registry [Recruiting]
Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However,
the peak prevalence of migraine is in women of childbearing age. This, coupled with the
sporadic nature of migraine attacks and high rates of unplanned pregnancies, makes
unintentional exposure to anti-migraine medications during pregnancy likely. Prior to an
anti-migraine medication being marketed there are few data available on drug safety in
pregnancy: data from animal models may not translate directly to humans and pregnant women
are routinely excluded from clinical trials. The Sumatriptan Pregnancy Registry was
established by GlaxoSmithKline (GSK) in 1996 to monitor the safety of sumatriptan during
pregnancy. It was combined with the Naratriptan Pregnancy Registry in 2001 and data
collection on the sumatriptan-naproxen combination (Treximet) began in 2008.
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction [Recruiting]
The purpose of this study is to determine whether naratriptan, a medication approved for
treatment of migraine, is effective in the treatment of post traumatic headache associated
with cognitive dysfunction.
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order [Recruiting]
In a double blind randomized clinical trial with cross-over design, treatment using
naratriptan will be compared to placebo within a group of 30 convicts with psychiatric
disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to
conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that
addition of naratriptan to the individual treatment regime reduces aggression - and improves
general outcome- as compared to addition of placebo and is well tolerated in this group and
under these conditions.
Reports of Suspected Amerge (Naratriptan) Side Effects
Overdose (5),
Drug Ineffective (4),
Chest Pain (4),
Stress Cardiomyopathy (4),
Photophobia (3),
Cataract (3),
Troponin T Increased (3),
Eye Pain (3),
Brain Natriuretic Peptide Increased (3),
Vasospasm (3), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Amerge has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Amerge review by 48 year old male patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | migraines |
| Dosage & duration: | | 2.5mg taken 3-4 times per week for the period of 6 yrs |
| Other conditions: | | high blood pressure |
| Other drugs taken: | | atenolol, hydrochlorothiazide, lisinopril | | |
Reported Results |
| Benefits: | | Amerge is effective in reducing the pain and associated symptoms of migraines. |
| Side effects: | | Mild drowsiness, sometimes mild nausea. |
| Comments: | | I have very severe migraine disease and have tried many different treatments. None are effective 100% of the time. In my experience, Amerge is the most effective for mild and moderate migraines (Nothing seems to work for severe attacks). I prefer Amerge because the beneficial effects seem to last longer than many of the other anti-migraine meds (often 18-24 hrs.). Also, side effects seem to be negligible(No palpitations and dizziness like with imitrex). The downside is that Amerge takes longer to work (2-4 hrs) than the other triptans. But because of the better safety profile and the longer duration of effectiveness, for me Amerge is a top choice for migraines. |
|
|
|
Page last updated: 2013-06-11
|
